BiotechTube
Home/Intellia Therapeutics/Jennifer Doudna, Ph.D.
JD

Jennifer Doudna, Ph.D.

Co-Founder

Intellia Therapeutics

Therapeutic Areas

Genetic DiseasesOncologyAutoimmune Conditions

Intellia Therapeutics Pipeline

DrugIndicationPhase
NTLA-2002 (lonvoguran ziclumeran)Hereditary Angioedema (HAE)Phase 3
NTLA-2001ATTR Amyloidosis (Cardiomyopathy/Polyneuropathy)Phase 3
NTLA-3001Hereditary Alpha-1 Antitrypsin Deficiency (AATD)Phase 1/2
NTLA-2003Glycogen Storage Disease Type Ia (GSDIa)Preclinical

Leadership Team at Intellia Therapeutics

JM
John M. Leonard, M.D.
President and Chief Executive Officer
LS
Laura Sepp-Lorenzino, Ph.D.
Executive Vice President, Chief Scientific Officer
DC
David C. Lubner
Executive Vice President, Chief Financial and Business Officer
JB
James B. Chung, M.D., Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
AP
Andrew P. May, Ph.D.
Executive Vice President, Chief Corporate Strategy Officer
View full Intellia Therapeutics profile